Related Experiment Video
Updated: Aug 27, 2025
09:48
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
434
Microvesicles: the functional mediators in sorafenib resistance.
Cong He1,2, Doulathunnisa Jaffar Ali1, Bo Sun1
1State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, Jiangsu, China.
Cancer Drug Resistance (Alhambra, Calif.)
|September 30, 2022
Summary
Microvesicles (MVs) are key in liver cancer drug resistance, transferring molecules that cause resistance. However, these MVs can also deliver therapies to reverse resistance, offering new treatment strategies.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Drug resistance is a major challenge in cancer therapy.
- The tumor microenvironment significantly influences treatment efficacy.
- Microvesicles (MVs) mediate intercellular communication and impact tumor progression.
Purpose of the Study:
- To review the role of MVs in liver cancer progression and treatment.
- To explore mechanisms of sorafenib resistance in hepatocellular carcinoma.
- To highlight the potential of MVs in overcoming drug resistance.
Main Methods:
- Literature review of studies on microvesicles and liver cancer.
- Analysis of mechanisms underlying sorafenib resistance.
- Evaluation of MVs as therapeutic carriers.
Main Results:
- MVs contribute to drug resistance by transferring functional molecules.
- MVs can be engineered as drug delivery systems to reverse resistance.
- Understanding MV function offers insights into novel therapeutic approaches.
Conclusions:
- Microvesicles play a dual role in liver cancer, promoting resistance and offering therapeutic potential.
- Targeting MVs could be a strategy to overcome sorafenib resistance in hepatocellular carcinoma.
- Further research into MVs may lead to precise, novel cancer therapeutics.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:15Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K